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Introduction
Lung vasculopathy is an irreversible pathologic hallmark 
of the lung vascular disorder pulmonary arterial hyperten-
sion (PAH). PAH is an often fatal and increasingly preva-
lent disease that is manifested by a maladaptive elevation 
of pulmonary vascular resistance and pulmonary arterial 
pressure, consequently leading to right heart failure and 
eventual death. Clinically, the disease is defined as a mean 
pulmonary artery pressure of >25 mmHg at rest [1].
There are three main forms of PAH; idiopathic (IPAH), 
in which the cause is unknown, familial (FPAH), and PAH 
associated with other risk factors (APAH), such as HIv 
infection, collagen vascular diseases, and congenital heart 
disease [2]. The main genetic defect associated with PAH is 
a mutation in the gene encoding bone morphogenetic pro-
tein receptor 2 (BMPR2). Germline mutations in BMPR2 
were originally identified in patients with FPAH [3, 4]. In 
these families, the disease segregates in an autosomal dom-
inant fashion, with markedly reduced penetrance of approx-
imately 20–30 % [5]. As such, many patients who carry the 
disease gene do not develop clinical PAH. In addition, up to 
25 % of patients with apparently sporadic IPAH have been 
found to harbor similar mutations [6]. A proportion of these 
mutation carriers are examples of FPAH where the condi-
tion has not manifested in relatives due to low penetrance, 
while others are examples of de novo mutations. The low 
penetrance of the disease among BMPR2 mutation carriers 
suggests that other factors are important in the manifesta-
tion of clinical PAH and that a “second hit” in addition to a 
mutation in BMPR2 is required to establish PAH [7].
The incidence of PAH varies from 1.1, 2.0, and 2.4 per 
million of adult population per year in the UK and Ireland, 
USA, and France, respectively [8–10]. Recent studies show 
that females are more susceptible to developing PAH with 
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a female-to-male ratio of 4.3:1 [11] in PAH and 4.1:1 in 
IPAH [12]. However, severity and survival is worse in 
males who have developed the disease than in females [13]. 
This clear difference between the genders is an intriguing 
phenomenon and much work is underway to identify the 
role of sex hormones such as estrogen on the development 
and maintenance of PAH.
Current treatments for PAH include endothelin-1 recep-
tor antagonists, phosphodiesterase type 5 inhibitors, and 
administration of prostacyclins [14]. Although current 
therapies do indeed provide a survival benefit, mortality 
rates still remain high and the treatment does not prevent 
the aggressive progression of the disease. As a result, newer 
treatments are required to more effectively manage PAH 
and regulate the cellular components resulting in pulmo-
nary remodeling. Contributing factors leading to remod-
eling include vessel injury, hypoxic exposure, and inflam-
mation, resulting in severe remodeling of predominantly 
the small pulmonary vessels [15]. This remodeling process 
involves interaction between all cell types present in the 
distinct layers of the pulmonary arteries causing histologi-
cal changes to the pulmonary vessel wall [16, 17] (Fig. 1).
The principal cell type within the adventitia layer of the 
vessel wall is the fibroblast, and adventitial thickening is 
observed due to hyperplasia of these cells [18, 19]. Activa-
tion of the fibroblasts results in a release of growth factors 
such as endothelin-1, serotonin, and platelet-derived growth 
factor (PDGF) [20] causing migration, proliferation, and 
contraction of fibroblasts and smooth muscle cells (SMC) 
[21]. An increase in reactive oxygen species (ROS) in the 
adventitia by NADPH oxidase can lead to activation of 
fibroblasts. From these activated adventitial fibroblasts, a 
subset population differentiate into myofibroblasts, char-
acterized by α-SMA expression [22]. Myofibroblasts are 
mesenchymal cells that can be induced under the control 
of growth factors such as transforming growth factor (TGF-
β1) [23]. These cells have the ability to migrate into the 
medial layer, increasing medial thickness. Another role of 
myofibroblasts is the production and deposition of extra-
cellular matrix proteins, such as collagen, elastin, fibronec-
tin, and tenascin-C, which can induce smooth muscle cell 
(SMC) proliferation and migration within the media [15, 
24, 25]. The medial layer within the vessel contains SMCs, 
which are regulated under the control of many growth fac-
tors and cytokines [26]. These factors influence the phe-
notype of the SMC inducing proliferation, migration, 
and contraction, while inhibiting apoptosis. Infiltration of 
the media with myofibroblasts and hypertrophy of SMCs 
results in muscularization of normally non-muscular or par-
tially muscular distal arteries augmenting medial thicken-
ing. Hypertrophy and excessive proliferation of endothelial 
cells (eC) contributes to increased intimal thickening and 
endothelial dysfunction, leading to an increase in vasocon-
strictor molecules, such as endothelin-1 (eT-1) [27]. It is 
suggested that eC dysfunction induces release of elastase, 
which activates matrix metalloproteinases (MMPs) and in 
Fig. 1  Pathogenesis of pulmonary arterial hypertension. Stress to the 
small pulmonary arteries results in endothelial dysregulation and pro-
liferation in the intima, smooth muscle cell proliferation, and resist-
ance to apoptosis within the medial layer, along with adventitial fibro-
blast activation. This culminates in vasoconstriction and remodeling 
of the pulmonary vessels, which can result in plexiform lesions in 
human PAH
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turn tenascin-C, therefore further enhancing SMC prolif-
eration in the medial layer [25, 28].
The progression of pulmonary arterial remodeling is 
through increased proliferation and resistance to apopto-
sis of eCs and SMCs. In particular, hyperproliferation of 
eCs can result in a clustered appearance resulting in the 
formation of complex plexiform lesions [29], occlusion of 
the blood vessel, and loss of blood flow to the small dis-
tal pulmonary arteries [30]. Although pulmonary arterial 
remodeling is a relatively well-studied condition, the exact 
cellular and molecular processes that lead to initiation and 
progression of PAH are still being investigated and are not 
completely understood. The process is proposed to be due 
to changes in transcriptional and signaling mechanisms 
within all three layers of the vessel wall. Thus, suggesting 
that controlling gene expression and hence protein expres-
sion, will allow modulation of the pathways involved in a 
cell-specific manner and result in more effective treatments 
for PAH.
miRNA biogenesis
MiRNAs are small non-coding RNA molecules around 
22 nucleotides long that target the 3′-untranslated region 
(UTR) of mRNA to negatively regulate gene expression 
[31, 32]. Transcription by RNA polymerase II gives rise 
to the primary miRNA (pri-miRNA) molecule, which can 
be over 1 kb in size and can produce several mature mi 
RNAs. This primary structure is processed by the RNase 
III enzyme Drosha in the presence of cofactor DGCR8 to 
form a ~60-nucleotide stem loop molecule; this is the pre-
cursor miRNA (pre-miRNA). Pre-miRNAs are transported 
out of the nucleus into the cytoplasm by exportin-5 where 
they are cleaved by the endonuclease Dicer into a micro-
RNA duplex. This duplex is then bound to an argonaute 
protein (Ago2) [33, 34] and the mature miRNA is formed 
by stabilization of the guide strand (identified by the suf-
fix 5p) while the passenger strand (identified by the suffix 
3p) was thought to be degraded, however, there is increas-
ing evidence that the function of 3p-derived miRNAs can 
be as important as the 5p strand [35, 36] (discussed below). 
The mature miRNA is incorporated into the RNA-induced 
silencing complex (RISC) where nucleotides 2–8 of the 
miRNA (“seed” region) bind to the 3′-UTR of the target 
mRNA sequence. If the complementarity between mRNA 
and miRNA is complete, cleavage of the mRNA occurs. 
However, if complementation is incomplete, inhibition of 
mRNA translation occurs, leading to gene silencing [32, 
37, 38] (Fig. 2). This results in miRNAs potentially regu-
lating a multitude of RNA species [39]. Of the non-coding 
RNA family, miRNAs are one of the largest families that 
have a relevant and well-studied function. Little is known 
about the other members of the non-coding RNA fam-
ily (e.g., long non-coding RNA, lncRNA) however, recent 
data implicates these lncRNAs in heart development [40] 
and consequently these molecules are likely to emerge as 
important regulators of tissue development within different 
disease models.
Although the majority of miRNAs follow the canoni-
cal biogenesis mentioned above, there are regulatory mol-
ecules that aid (or indeed impede) formation of the mature 
miRNA, thus illustrating how different miRNAs are pro-
cessed by distinct methods [41]. KH-type splicing regula-
tory protein (KHSRP) has been found to bind to the ter-
minal stem loop of certain pre-miRNAs (in particular 
pre-miR-21 and pre-miR-126a) within the nucleus to help 
recruit exportin-5 and therefore stimulate miRNA matu-
ration [42]. Similarly, HIv trans-activating response RNA 
binding protein (TARBP2) can work in concert with Dicer 
to stabilize the miRNA-Dicer complex as well as ensure 
efficient recruitment of Ago2 [43]. Conversely, nuclear 
factor 90 (NF90) and NF45 are found within the nucleus 
and form a complex that binds to the pri-miRNA, thereby 
preventing Drosha from cleaving the primary miRNA. This 
results in reduced levels of pre-miRNA and in turn mature 
miRNA [44]. It has also been discovered that distinct mi 
RNAs are capable of being processed in a Dicer-independent 
manner. In particular, miR-451 precursor is a short stem 
loop sequence and is loaded directly into Ago2 [45, 46]. 
Of the four argonaute proteins found to be ubiquitously 
expressed in humans, Ago2 is responsible for the direct 
cleavage of mRNA when working in concert with RISC. 
As well as this, Ago2 can also act as an endonuclease and 
hence cleaves pre-miR-451 independent of Dicer [33, 34, 
45, 46].
Until recently, it was thought that the guide strand was 
always incorporated into the RISC complex and the passen-
ger strand was degraded with no biological role. However, 
evidence now suggests that both stands of the duplex can 
have functional roles and both may be important in differ-
ent signaling cascades [35, 36]. A recent study by eulalio 
[35] found that ectopic expression of miR-590-3p and miR-
199-3p increased cardiomyocyte proliferation both in vitro 
and in vivo, illustrating the new emerging role for the 3p 
strand of the miRNA duplex.
Owing to their pleiotropic vascular effects, miRNAs 
are thought to function as upstream molecular factors that 
integratively coordinate pathogenic signaling pathways in 
PAH. A spectrum of PAH-relevant insults such as hypoxia 
and inflammation are essential modulators of miRNA 
expression in vascular cells. Consequently, a number of 
these dynamically regulated miRNAs are thought to be 
central regulators in vascular homeostasis essential for 
thrombosis, metabolism, cellular proliferation, and cell 
fate. Despite this, only a distinct few miRNAs have been 
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molecularly linked to PAH. Hence, there are undoubtedly 
a significant number of presently unidentified miRNAs 
that have an essential role in pulmonary vascular function. 
Due to the complex molecular pathology of this disease, 
the combined utilization of bioinformatics and experimen-
tal biology may be especially pertinent in deciphering the 
pervasiveness of miRNA biology in PAH. This review will 
provide a comprehensive overview concerning miRNA 
function in pulmonary vascular homeostasis and discuss 
the contribution of miRNA biology in pulmonary vascular 
remodeling and disease. we will also speculate on the elu-
cidation of presently unknown miRNAs in PAH and com-
ment on the exciting application of miRNA-based therapies 
in the treatment of pulmonary vascular disease.
BMP pathway in pulmonary remodeling
There is a large cohort of data implicating the BMP path-
way in the etiology of PAH as heterozygous mutations 
within the gene encoding bone morphogenetic protein type 
II receptor (BMPR2) have been found in ~70 % of FPAH 
[3, 4] and ~26 % of IPAH cases [6]. BMPR2 is a serine/
threonine receptor kinase that binds the TGF-β superfamily 
of ligands. The resulting outcome of BMP signaling is cell 
and site specific. Under normal conditions, BMP-4 signals 
via a SMAD-dependent pathway to inhibit proliferation 
in pulmonary artery SMCs (PASMCs) [47]. TGF-β often 
antagonizes the effect of BMP signaling and is thought 
to signal through the activin receptor like kinase (ALK5) 
and Smad-2 and -3 [48]. The BMP signaling pathway is 
also controlled by a number of negative regulatory mol-
ecules, such as Smad-6/-7, which inhibit phosphorylation 
of Smad-1 and -5 [49, 50] and Smad ubiquitin regulatory 
factor 1 (Smurf1) resulting in degradation of Smad-1 and 
-5 [51]. Chan et al. [52] illustrated that certain proteins 
interact with the terminal domain of BMPR2 (BMPR2-
TD), in particular Tribbles 3 (Trb3). Upon BMP4 stimula-
tion of BMPR2, Trb3 dissociates from the terminal domain 
of the receptor and binds to Smurf1 inducing degradation 
of Smurf1 via the ubiquitin–proteasome pathway. Reduc-
tion in Smurf1 increases signaling through the BMP-Smad-
dependent pathway and promotes the contractile phenotype 
in vascular SMCs [52].
Many mutations have been discovered within the 
BMPR2 gene encoding region from patients diagnosed 
with PAH. However, kindred studies have shown that only 
~20 % of people with these mutations go on to develop 
Fig. 2  MiRNA biogen-
esis. Transcription by RNA 
polymerase II gives rise to the 
pri-miRNA, which can produce 
multiple mature miRNAs. Pro-
cessing by RNase III enzyme 
Drosha along with cofactor 
DGCR8 produces the stem-loop 
pre-miRNA which is exported 
out of the nucleus by expor-
tin-5. In the cytoplasm, cleavage 
by Dicer results in an miRNA 
duplex, ~22 nucleotides long. 
The mature miRNA is incor-
porated into the RNA-induced 
silencing complex (RISC) and 
targets the 3′-UTR of mRNA. 
Gene silencing is achieved by 
either mRNA degradation or 
translational repression
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PAH [5], thus indicating that there may be environmental 
or additional genetic risk factors involved. PAH patients 
with a heterozygous mutation in the gene encoding BMPR2 
demonstrate lowered levels of BMPR2 protein [53] and 
PASMCs from these patients have an altered response to 
the BMP growth factors [54]. Similarly, animal models 
of PAH show a reduction in BMPR2 protein levels in the 
lungs [55]. Genetic ablation of BMPR2 proves lethal due 
to lack of mesoderm [56], while BMPR2+/− mice do not 
spontaneously develop PAH. However, when BMPR2+/− 
mice are exposed to a secondary insult (e.g., serotonin), 
increased pulmonary artery pressures and pulmonary 
remodeling ensues [57]. This strengthens the idea that 
BMPR2 mutations predispose patients to develop PAH and 
that other factors are involved in developing the disease.
Screening of miRNAs dysregulated in PAH
The first study to report dysregulation of miRNAs during 
the development of PAH was by Caruso et al. [58]. Using a 
microarray followed by validation by quantitative polymer-
ase chain reaction, it was found that miR-22, miR-30, and 
let-7f were downregulated while miR-322 and miR-451 
were upregulated in two commonly used rodent models 
of PAH (exposure to chronic hypoxia and monocrotaline 
(MCT) insult in the rat) [58]. Another study showed that 
in human pulmonary arteries from PAH patients, miR-138, 
miR-367, miR-27b, miR302b, miR-145, and miR-450a 
were up-regulated while miR-204 was down-regulated 
compared to control patient pulmonary arteries [59]. This 
fundamental work highlighted the possible role of specific 
miRNAs during disease development.
In contrast, others have used a candidate approach to 
identify miRNAs involved in the remodeling process. Mi 
RNAs which affect signaling pathways involved in the phe-
notypic changes during remodeling are studied along with 
their target genes, focusing specifically on the changes in 
expression during disease initiation and progression [60].
miR‑204
An elegant study by Courboulin et al. [59] was the first 
to confirm a mechanistic link between miRNAs and cel-
lular pathways affecting pulmonary arterial remodeling. 
MiR-204 is located within and transcribed from intron 6 
of the transient receptor potential melastatin 3 (TRPM3) 
gene on human chromosome 9. MiR-204 and TRPM3 
are transcribed as a single unit [61] however, the effects 
of miR-204 on signaling pathways involved in PAH do 
not appear to be mediated via TRPM3 [59]. MiR-204 has 
been implicated in the development of several tissues (e.g., 
maintaining epithelial barrier function in eye development 
[62]) and disease states. The expression of miR-204 has 
been linked with survival rate in neuroblastoma [63] and 
miR-204 is found to be down-regulated in tumor tissue 
from gastric cancer patients [64]. Both studies found that 
miR-204 directly targets Bcl-2 (B cell lymphoma 2), an 
inhibitor of apoptosis and with suppressed levels of miR-
204, Bcl-2 levels were de-repressed therefore promoting 
inhibition of apoptosis [63, 64].
with regard to pulmonary remodeling, miR-204 was 
first observed to be dysregulated in the MCT and hypoxic 
rat model of PAH with levels of miR-204 down-regulated 
in the lungs from the disease model [58] as well as in the 
hypoxic mouse lung [59]. In situ hybridization demon-
strated localization of miR-204 within the PASMC com-
partment and miR-204 expression was reduced in PASMCs 
from IPAH patients, accompanied by increased levels of 
proliferation and lower levels of apoptosis compared to 
control PASMCs. Additionally, treatment of MCT rats with 
synthetic miR-204 mimic significantly lowered pulmonary 
artery pressure and medial wall thickness in small pulmo-
nary arteries [59]. It will be important to define, for poten-
tial therapeutic purposes, the optimal mimic delivery strat-
egy that leads to effective and safe mimic administration to 
the pulmonary vascular compartment in vivo.
The effect of miR-204 on proliferation and apoptosis is 
proposed to be via the Src-STAT3-NFAT/BMPR2 pathway 
(Fig. 3). During the initiation of PAH, circulating vasocon-
strictor molecules such as endothelin-1 and PDGF activate 
STAT3, which can directly bind to miR-204 leading to 
down-regulation of this miRNA. This causes an increase in 
miR-204 target gene SHP2, a tyrosine phosphatase involved 
in growth factor signaling, leading to activation of Src and 
increasing STAT3 activation [59]. This positive feedback 
of STAT3 may indicate why the progression of pulmonary 
arterial remodeling is so severe. STAT3 has been shown to 
directly activate the serine/threonine protein kinase Pim1 
which in turn triggers activation and nuclear translocation 
of NFATc2. In vivo inhibition of Pim1was able to reverse 
MCT-induced PAH in rats while Pim1−/− mice were resist-
ant to PAH development [65]. NFATc2 is up-regulated in 
pulmonary arteries from PAH patients [66] and animal 
models of PAH have illustrated a down-regulation of volt-
age-gated potassium channels, in particular Kv1.5 [67]. 
A key study by Bonnet et al. [66] found that NFATc2 activa-
tion decreased the expression of Kv1.5 resulting in PASMC 
depolarization and opening of the voltage gated calcium 
channels, hence increasing intracellular levels of potassium 
([K+]i) and calcium ([Ca2+]i). Increased [Ca2+]i promotes 
further NFATc2 activity and leads to vasoconstriction and 
PASMC proliferation [68]. NFATc2 also increased anti-
apoptotic Bcl-2 leading to mitochondrial hyperpolariza-
tion and resistance to apoptosis [66]. Treatment of PAH 
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PASMCs with vIvIT (a direct inhibitor of NFAT) or cyclo-
sporine A (an indirect inhibitor of NFAT), lowered levels 
of nuclear activated NFATc2, reduced [K+]i and [Ca2+]i 
and depolarized PASMC mitochondria to levels compa-
rable to normal PASMCs. Similar results were obtained 
in vivo using cyclosporine A, with inhibition of NFATc2 
reversing MCT-induced PAH by increasing expression of 
Kv1.5, reducing Bcl-2 levels and promoting mitochondrial-
dependent apoptosis. This culminated in reduced right ven-
tricular hypertrophy (RvH) and medial hypertrophy of the 
small pulmonary arteries [66]. 
Administration of phenamil, a derivative of the diuretic 
amiloride, to the hypoxic rat model of PAH caused a reduc-
tion in PAH development and pulmonary remodeling. This 
is thought to be due to phenamil inducing Trb3 therefore 
increasing signaling through the BMP pathway and result-
ing in pro-proliferative and anti-apoptotic PASMCs [52, 
69]. These findings highlight an essential role of miR-
204 in controlling PASMC proliferation and apoptosis via 
NFAT regulation. There are many molecules involved in 
the NFAT signaling pathway and modulating either miR-
204 or down-stream effectors may provide a target for 
future therapy of pulmonary remodeling. Consideration 
has to be given to the method by which these pathways 
are modulated. Over-expression of miR-204 via synthetic 
miR mimics would require optimization of mimic delivery 
to target specifically the pulmonary vasculature therefore 
limiting off-target effects. Although much work is required 
to further the present data and before a viable therapeutic 
agent is produced, the work shows promise.
Fig. 3  MiRNA regulatory pathways. Summary schematic illustrat-
ing the complex pathways controlled by miRNAs. Dysregulation of 
endothelial cells (EC) and smooth muscle cells (SMC) can occur in 
response to stress or injury to the vessel leading to vasoconstriction 
and pulmonary arterial remodeling
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miR143/145 cluster
Smooth muscle cells (SMCs), one of the key cellular com-
ponents of pulmonary vascular remodeling, are able to 
“phenotypically switch” between the quiescent “contrac-
tile” phenotype and the migratory and proliferative “syn-
thetic” phenotype in response to different growth factors 
to induce repair during vascular injury [70, 71]. Persistent 
activation of the highly proliferative synthetic state can be 
detrimental and lead to disease progression [72]. Two of 
the key miRNAs involved in regulation of the phenotype of 
SMCs are miR-143 and miR-145. MiR-145 is transcribed 
bicistronically along with miR-143 from human chromo-
some 5 [73]. expression of the miR-143/miR145 cluster 
is high in cardiomyocytes during heart development, after 
which expression is exclusively localized within the SMCs 
[73–75]. Activation of miR143/miR145 is highly regulated 
through a DNA element called CArG box, contained within 
the promoter region of the pri-miRNA cluster, which is 
activated by binding of serum response factor (SRF) and 
its cofactors myocardin (Myocd) and myocardin-related 
transcription factors (MRTF) [73]. Growth factors TGF-β 
and BMP4 have been shown to activate miR-143/miR-145 
via distinct mechanisms. TGF-β induces Myocd expression 
while BMP4 stimulation leads to MRTF-A activation, both 
pathways resulting in activation of miR-143/miR-145 clus-
ter via the CArG box [70, 76, 77].
with relevance to PAH, miR-143 and miR-145 can 
potentially target many of the same genes, leading to 
co-operativity of this cluster in translational regulation. 
Down-regulation of target genes klf4 and klf5 by activa-
tion of miR-143/miR-145 (via TGF-β and BMP4) increases 
expression of smooth muscle-specific genes such as SMA, 
calponin, and SM22-α, promoting differentiation and 
repression of proliferation in vascular SMCs [75, 76, 78, 
79]. It has also been shown that klf4 down-regulates Myocd 
and MRTF-A, two of the critical signaling molecules 
involved in promoting the contractile phenotype via miR-
143/miR-145 activation [76, 78]. Another transcription 
factor, klf2, has been shown to bind to a promoter region 
within the miR-143/miR-145 cluster up-regulating expres-
sion of this miRNA cluster [80] and stimulating cell–cell 
communication between eCs and SMCs. Klf2 has been 
shown to generate the atheroprotective effects in human 
eCs in response to shear stress, one of the major contrib-
uting factors of atherosclerosis [80, 81]. A recent study 
revealed that over-expression of klf2 in human umbilical 
vein endothelial cells (HUveCs) led to an up-regulation of 
miR-143 and miR-145 within the HUveCs but also within 
the extracellular vesicles released by these cells. These 
vesicles were then able to control the phenotype of co-cul-
tured SMCs by down-regulating target genes of miR-143/
miR-145, therefore promoting the contractile phenotype 
[80]. Further to this, intravenous injection of extracellular 
vesicles from eCs known to have elevated Klf2 expression 
reduced atherosclerotic lesion formation in the Apoe−/− 
mouse [80].
Recent studies have demonstrated an SRF-independent 
pathway of miR-143/miR-145 activation [82]. Jag-1 acti-
vates translocation of notch intracellular domain, which 
can then interact with CBF1 regulators. This complex binds 
to the miR-143/miR-145 promoter region (independent of 
the CArG box) resulting in up-regulation of SMC contrac-
tile genes [82]. These critical studies emphasize the impor-
tance of miR-143/miR-145 in regulating and maintaining 
vascular SMC phenotype under normal conditions.
The SMC phenotypic switch is clearly integral to the 
pathogenesis of vascular diseases and hence many studies 
have reported the involvement of miR-143/miR-145 in this 
setting. expression of miR-143/miR-145 was significantly 
reduced in animal models characterized by neointimal for-
mation, including carotid artery ligation, carotid artery bal-
loon injury, transverse aortic constriction (TAC), and Apoe 
knockout mice [75, 79, 83]. Additionally, over-expression 
of miR-145 in models of vascular disease has resulted in 
reduced neo-intimal formation and increased expression 
of SMC genes, indicative of the contractile phenotype [79, 
83]. Use of miR-143/miR-145 knockout mice supports 
these results with increased neo-intimal formation com-
pared with wild-type mice [74, 79]. Xin et al. [73] found 
opposing results with miR-143 and miR-145 knockout 
mice displaying reduced neo-intimal formation in response 
to carotid artery ligation. However, this result is thought 
to be due to maladaption of the knockout mice to injury. 
while these studies highlight the importance and implica-
tion of this axis in vascular pathology, they do not directly 
assess the influence of the miRNAs in PAH.
In the setting of PAH, recent work established that miR-
145 was up-regulated in pulmonary arteries from IPAH 
patients [59], PAH-PASMCs containing a known BMPR2 
mutation, and in lung tissue from IPAH and FPAH patients 
[84]. expression of miR-145 was noted within the muscu-
lar regions of the lesions [84] with greater expression of 
miR-145 in the concentric lesions compared to plexiform 
lesions [85]. MiR-145 expression was also significantly 
increased in the hypoxic mouse model of PAH, both in 
the lungs and the right ventricle. Furthermore, knockout 
of miR-145 by both the use of miR-145−/− mice and mice 
treated with antimiR-145 significantly reduced the systolic 
right ventricular pressure (RvP) and number of remod-
eled vessels compared to control hypoxic animals. Target 
analysis provides evidence that members of the wnt sign-
aling pathway are targets for miR-145. wIF1, FRZB, and 
DAB2, which are part of the wnt signaling family, were 
increased in hypoxic miR-145−/− mice [84]. In addition 
to this, other members of the wnt signaling pathway have 
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previously been shown to regulate PASMC proliferation 
[86], thus illustrating that the protective remodeling effect 
observed in miR-145−/− mice may be due to inhibition of 
wnt/β-Catenin canonical signaling pathway. Loss of miR-
143 did not illustrate the same protective effect as miR-145 
[84] however, further studies are required to ascertain the 
exact role of miR-143 in the pulmonary vasculature and the 
remodeling process. Taken together, in vitro studies have 
demonstrated the essential role for miR-143/miR-145 for 
controlling SMC phenotype. Studies in vivo using rodent 
models of PAH indicate that specifically knocking down 
miR-145 expression appears to confer protection against 
development of PAH. Consequently, miR-145 may be tar-
geted as treatment for pulmonary diseases once more is 
known about the exact pathways activated within the pul-
monary vasculature in response to modulation of miR-145.
miR‑17/92 cluster
As well as regulating the NFAT pathway, miR-204 has also 
been implicated in regulating the BMPR2 pathway indi-
rectly as miR-204 has been shown to regulate the cytokine 
interleukin-6 (IL-6). IL-6 has been shown to be involved in 
PAH development as levels are increased in PAH patients 
and over-expression of IL-6 induces PAH in mice [87]. In 
human pulmonary artery endothelial cells (PAeC), IL-6 
induces expression of the miR-17/92 cluster via activation 
of STAT3, which can directly bind to the promoter region 
of the miR-17/92 cluster (specifically miR-20a). BMPR2 
is a target for this miR cluster and accordingly, BMPR2 
protein levels are down-regulated in response to IL-6 [88]. 
Both miR-204 and miR-17/92 cluster are activated through 
different mechanisms but there are common molecules to 
both signaling pathways, indicating the importance of mi 
RNAs working in concert with one another to affect cel-
lular phenotype.
MiR-17/92 is a polycistronic cluster located on human 
chromosome 13, which gives rise to six mature miRNAs; 
miR17, miR-18a, miR-19a, miR-20a, miR-19b-1, and 
miR-92-1 [89]. Although all six miRNAs are transcribed 
together, each miRNA will regulate its own set of targets. 
Hence, regulation of the miR-17/92 cluster has the poten-
tial to control a great deal of target genes. The miR-17/92 
cluster was first identified to be involved in tumor develop-
ment due to up-regulation in tumor cells [90]. O’Donnell 
et al. [91] demonstrated that activation of the miR-17/92 
cluster was via the transcription factor c-Myc. MiR-17-5p 
and miR-20a down-regulate target gene e2F1, which is 
involved in control of cell cycle and can induce c-Myc in 
a feedback loop. The miR-17/92 cluster is highly involved 
in controlling tumor growth via regulation of prolifera-
tion and apoptosis [92] and another cell cycle regulator, 
cyclin-dependent kinase inhibitor 1A (p21), is also targeted 
by miR-17. Inhibition of miR-17 in the hypoxic mouse and 
MCT rat model of PAH caused a reduction in systolic RvP 
and pulmonary vascular remodeling with an increase in 
p21 expression [93]. The exact mechanisms through which 
this miRNA cluster are acting are still relatively unknown, 
therefore further knowledge must be gained before we can 
understand the true role of this cluster in the pulmonary 
vasculature.
miR‑424/503
Recent work has highlighted the role of miR-424/503 in 
PAH. MiR-424 and miR-503 are located within 250 base 
pairs of each other on the human X chromosome and 
are transcribed together [94]. The influence of these mi 
RNAs on pulmonary remodeling has been suggested due 
to their activation by Apelin. Apelin is highly expressed in 
pulmonary endothelial cells and expression is decreased 
in lung eCs and in serum from IPAH and FPAH patients 
[94, 95]. Apelin−/− mice were shown to develop exagger-
ated PAH when exposed to hypoxia with obliteration of 
the small pulmonary arteries, compared to wild-type mice 
[95]. This finding was proposed to be via Apelin target-
ing AMP-activated kinase, which in turn activates klf2 to 
regulate endothelial nitric oxide synthase (eNOS) produc-
tion [95]. Kim et al. [94] then found that decreased apelin 
expression in PAeCs resulted in up-regulation of fibroblast 
growth factor 2 (FGF2) and increased proliferation. This 
study postulates that apelin can target miR-424 and miR-
503 in PAeCs, which can then directly repress FGF2 and 
FGFR1. Over-expression of these two miRNAs resulted 
in down-regulation of FGF2 and FGFR1, reducing phos-
phorylation of eRK1/2 and inhibition of proliferation [94, 
96]. Furthermore, PAeCs regulate PASMCs in a paracrine 
fashion as exposure of PASMCs to media conditioned by 
PAH PAeCs led to hyperproliferation of PASMCs due to 
increased FGF2 expression [97]. Lentiviral over-expression 
of miR-424 and miR-503 in the lung of animal models of 
PAH reduced systolic RvP, RvH, muscularization of small 
pulmonary arteries and decreased proliferation, highlight-
ing the protective effect of miR-424 and miR-503 in the 
pulmonary vasculature [94]. From these studies, apelin 
appears to have a critical function in controlling both PAeC 
and PASMC phenotype via down-stream signaling.
The role of miR‑21 in PAH
MiR-21 is located on human chromosome 17 within the 
coding gene for transmembrane protein 49 (TMeM49), 
however miR-21 has its own promoter region and is 
4487MicroRNAs in pulmonary arterial remodeling
1 3
therefore transcribed independently [98]. The role of miR-
21 in pulmonary arterial remodeling has been investigated 
in many cell types and in vivo models. As stated before, 
hypoxia is one of the main triggers for pulmonary remod-
eling and miR-21 expression is up-regulated in human 
PASMCs [99], human PAeCs [60], and mouse lungs [93, 
100] exposed to hypoxia. Increased PASMC proliferation 
and migration in hypoxic PASMCs or control PASMCs 
over-expressing miR-21 has been observed, with rever-
sal of phenotype with treatment of antimiR-21 [99, 100]. 
Down-regulation of miR-21 target genes PDCD4, SPRY2, 
and PPARα may be responsible for the increased prolif-
eration observed [99, 101] and reduction in PDCD4 has 
recently been proposed to have anti-apoptotic effects [102].
Bone morphogenetic protein (BMP) signaling also plays 
a part in modulating miR-21 activation once again in a 
ligand-specific manner. BMP4 stimulates SMAD-1 and -5, 
while TGF-β stimulates SMAD-3, to bind to the RNA heli-
case p68, which is part of the Drosha complex. This com-
plex promotes processing of pri-miR-21 into pre-miR-21, 
therefore increasing mature-miR-21 expression, which can 
down-regulate target genes such as PDCD4, resulting in 
increased smooth muscle contractile gene expression [101]. 
Upon induction of miR-21 by BMP4, members of the dedi-
cator of cytokinesis (DOCK) 180-related protein family 
(DOCK-4, -5 and -7) were down-regulated. A reduction 
in DOCK protein leads to an inhibition of cell migration 
and promotion of the contractile SMC phenotype [103], 
thus illustrating another miRNA that can modulate PASMC 
phenotype via BMP signaling.
Tissues taken from patients with heart failure and ani-
mal models of cardiac disease show an up-regulation of 
miR-21 [104, 105]. However, two separate groups have 
found opposing results regarding therapeutically regulating 
miR-21 in the heart. Thum et al. [104] found that the sig-
nificant up-regulation of miR-21 in cardiac fibroblasts after 
TAC lead to repression of its target Sprouty homologue 1 
(Spry1), resulting in activation of eRK-MAP kinase sign-
aling pathway and increased cell survival. Treatment with 
antagomiR-21 was able to reverse these changes, lead-
ing to a reduction in fibrosis [104]. On the contrary, Pat-
rick et al. [105] found that a reduction in miR-21 did not 
influence cardiac hypertrophy and fibrosis. In response to 
various cardiac injuries, including TAC, infusion of AngII 
and coronary artery ligation, miR-21−/− mice showed com-
parable phenotypes to the wild-type mice with increased 
remodeling and fibrosis, with similar results obtained using 
an LNA-antimiR targeting miR-21 [105]. The differences 
observed between these two studies may be due to differ-
ences in chemistry between the oligonucleotides used for 
miR-21 knock down. These studies indicate the possible 
challenges faced when using knock down of a miRNA as a 
target for prevention and reversal of the diseased state.
Similar to the controversy surrounding miR-21 in car-
diac disease, conflicting results have also been obtained 
from in vivo experiments regarding the role of miR-21 
in PAH. Knock down of miR-21 in hypoxic mice using 
antimiR-21 resulted in a reduction in systolic RvP [93] 
and lowered muscularization of distal pulmonary arteries, 
thought to be brought about by a reduction in fibronectin, 
endothelin-1, α-SMA, Cald1 and SM22-α [100]. On the 
contrary, Parikh et al. [60] observed an exaggerated PAH 
phenotype in mice void of miR-21 expression in the pul-
monary vasculature after exposure to Sugen-5416 (vascu-
lar endothelial growth factor receptor inhibitor) coupled 
with chronic hypoxia with an increase in systolic RvP 
and increased pulmonary arterial remodeling shown by 
increased muscularization in the arterial wall. This ampli-
fied response may be due to repression by RhoB, a target of 
miR-21. RhoB expression induces Rho-kinase activation, 
which attenuates endothelial nitric oxide synthase, leading 
to pulmonary vasoconstriction [60]. To support this data, 
RhoB knockout mice have reduced pulmonary remodeling 
and RvH when exposed to hypoxia [106].
Conversely, another study has reported that expression 
of miR-21 was decreased in male rats exposed to MCT 
with expression unchanged in hypoxic conditions and 
down-regulation of miR-21 also observed in lung samples 
from IPAH patients [58]. The variation between the studies 
mentioned may be due to multiple experimental variations, 
including differences in species and distinct methods used 
to modulate miR-21 levels as mentioned above. Another 
possibility that may lead to differences in findings could be 
gender. Both males and females are known to have different 
susceptibility to developing PAH and therefore the miRNA 
profile may be modulated differently between the sexes. 
Taken together, these findings highlight the importance 
of miR-21 in pulmonary remodeling, however, the exact 
mechanism of action of miR-21 appears to be dependent on 
various experimental factors.
Other pathogenic mechanisms linking miRNAs  
and PAH
Resistance to apoptosis is a major component leading to the 
development of pulmonary remodeling and recent work has 
highlighted the role of p53 and miR-34a [107]. MiR-34a 
is located on human chromosome 1 and pri-miR-34a is a 
direct target for the tumor suppressor protein p53. Thus, 
miR-34a is thought to be involved in various cancer path-
ways [108, 109]. Over-expression of miR-34a leads to a 
reduction in proliferation and augmented apoptosis [110–
112]. A study by Mizuno et al. [107] demonstrated that 
hypoxia up-regulates p53 and in turn miR-34a. Accord-
ingly, p53 knockout mice display an exaggerated PAH 
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phenotype with increased systolic RvP, RvH, and medial 
wall thickening in small pulmonary arteries when exposed 
to hypoxia compared with hypoxic wild-type mice [107]. 
Notch1 has been verified as a direct target for miR-34a 
[113], thus over-expression of miR-34a down-regulates 
Notch1 and its downstream targets Bcl-2 and Survivin 
[110, 112], both of which are anti-apoptotic. Although 
the majority of studies reporting the p53/miR-34a/Notch1 
pathway have examined the role in cancer, the pathogenesis 
of cancer and remodeling share several common features, 
however, further studies will confirm if the same response 
is initiated in pulmonary artery cells.
MiR-328 is primarily localized within the PASMC and 
is found to be down-regulated in pulmonary arteries from 
hypoxic rats and PAH patients. Over-expression of miR-
328 in rat PASMC displayed an increase in cellular apop-
tosis and insulin growth factor 1 receptor (IGF-1R) was 
identified as a target for miR-328 [114]. This data impli-
cates miR-328 in remodeling by regulating the apoptotic 
pathway, although the exact molecules and targets involved 
in the apoptosis response via miR-328 need to be further 
clarified.
Another miRNA thought to be involved in remodeling 
is miR-206. MiR-206 is down-regulated in PASMCs from 
hypoxic mice and hPASMC proliferation and migration 
is reduced with over-expression of miR-206, along with 
increases in smooth muscle cell markers therefore pro-
moting the contractile phenotype. Furthermore, hPASMCs 
over-expressing miR-206 demonstrate increased apoptotic 
activity, as shown by TUNeL staining and caspase 3 activ-
ity [115], indicating that lowered expression of miR-206, 
as in the case during PAH and hypoxia, promotes exces-
sive proliferation and resistance to apoptosis in PASMCs. 
The mechanism of action is thought to be due to repres-
sion of notch3 by miR-206 as notch3 has been shown to 
increase SMC growth and prevent SMC apoptosis [116, 
117]. Little is known about miR-206 in disease develop-
ment with previous studies showing its involvement in 
regulation of breast cancer cell lines [118]. with further in 
vivo work focusing on up-regulation of miR-206, the path-
ways and molecules involved in miR-206 modulation can 
be identified.
What causes miRNA dysregulation?
The focus of this review has primarily been on the events 
occurring downstream of miRNA and the ensuing changes 
in gene regulation and phenotype. However, it is fun-
damentally important to understand the mechanisms by 
which these miRNAs are initially regulated during dis-
ease. Hypoxia is one of the major rodent models used to 
study PAH and in addition to this, hypoxia can occur in 
site-specific regions in response to inflammation or vas-
cular injury. Therefore, one of the key triggers for miRNA 
dysregulation may be activation of transcription factors, 
such as hypoxia inducible factors (HIF), which promote 
regulation of many pathways in response to hypoxic con-
ditions. Mice heterozygous for HIF1α had reduced pulmo-
nary remodeling compared to wild-type mice [119], indi-
cating that HIF1 plays a vital role in controlling vascular 
remodeling in response to hypoxia. Numerous miRNAs 
have been identified as being dysregulated in hypoxic con-
ditions in a HIF-dependent manner [120]. Recent studies 
have found that miR-210 expression is induced by HIF1α 
in pancreatic cancer cells [121] and endothelial cells [122] 
therefore providing a possible explanation as to why HIF1α 
activation can result in gene silencing. As well as induc-
ing miRNA expression, HIF1α can also be targeted by mi 
RNAs to provide a complex and interactive signaling path-
way. One such example is miR-155, which has been shown 
to provide a negative feedback loop involving HIF1α in 
hypoxic conditions [123].
The cellular response to hypoxia is only one aspect 
that may promote changes in miRNA expression during 
disease. Another factor thought to be involved in miRNA 
dysregulation is inflammation. Inflammation is an impor-
tant process thought to contribute to PAH phenotype due 
to the release of cytokines, chemokines, and various growth 
factors which can result in cellular proliferation, migration 
and survival. Due to their extensive gene regulatory effects, 
miRNAs may be involved in the regulation of inflamma-
tion, and as a result have an impact on the pathogenesis 
of PAH. In support of this, Kuhn et al. [124] observed 
that miR-25 was down-regulated in human airway SMCs 
in response to pro-inflammatory stimuli including IL-1β, 
TNF-α, and IFN-γ, while Klf4, a target gene of miR-25, 
was increased. On the other hand, several miRNAs includ-
ing miR-155 [125, 126] and miR-146 [126] are induced 
by various inflammatory mediators. MiR-146a is induced 
in response to pro-inflammatory stimuli via NF-κB and 
targets TRAF6 and IRAK1which are molecules involved 
in NF-κB activation, thus providing a negative feedback 
loop [126]. various studies have found an up-regulation of 
miR-21 expression after exposure to inflammatory stimuli 
including heat-inactivated bacterium [127], LPS expo-
sure [128], and in a model of allergic airway inflammation 
[129]. In particular, transcription of pri-miR-21 has been 
shown to be induced by IL-6, a pro-inflammatory cytokine, 
in a STAT3-dependent manner [130] and it is believed that 
initial IL-6 release is due to NF-κB nuclear translocation 
in response to tissue damage [131]. The fact that miRNAs 
can be modulated by inflammation as well as target inflam-
matory mediators adds to the complexity of this regulatory 
pathway, making it a challenging task to study in a disease 
model.
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Another possible mechanism through which miRNAs 
are modulated may be through tyrosine kinase pathways. 
The majority of growth factors (such as PDGF and vas-
cular endothelial growth factor, veGF) signal through 
tyrosine kinase receptors that can activate STAT proteins. 
Recent research has highlighted the function of miRNAs 
in this pathway as several miRNAs have been shown to be 
regulated by tyrosine kinase Src and STAT3, in particular 
miR-204 [59] and miR-17/92 [88] (see individual sections 
above and Fig. 3). There is strong evidence linking tyrosine 
kinase dysregulation and signaling dysfunction in disease 
as the tyrosine kinase inhibitor imatinib was developed 
as a treatment for chronic myeloid leukemia [132]. Many 
of the pathologies associated with PAH share similarities 
with cancer and as a result, imatinib has been the subject 
of a phase 3 trial as an “add-on” therapy for PAH [133]. 
Imatinib treatment caused an increase in exercise capacity 
and improved hemodynamic parameters, however, adverse 
effects were recorded that limit clinical application in the 
setting of PAH. Hence, more knowledge is required regard-
ing the exact mechanisms by which tyrosine kinases exert 
their effect within the pulmonary circulation and miRNAs 
may provide a crucial link into the downstream effects of 
this pathway.
One way to characterize the exact processes that are 
initiating miRNA dysregulation in PAH would be to use 
a bioinformatics approach, as has been utilized previously 
[60]. This would allow pathways activated during PAH to 
be identified and assess the precise mechanisms by which 
miRNAs are affected. The information gathered from a 
screening approach would add to the knowledge already 
known about the downstream effectors of these miRNAs 
and create a better picture of PAH disease initiation and 
progression through miRNA pathways.
miRNAs as biomarkers for disease
The studies presented within this review demonstrate that 
expression of miRNAs are tissue and cell specific and can 
be dysregulated during disease. More importantly, many 
miRNA expression levels correlate with disease severity. 
This provides a unique signature of miRNAs which are 
expressed in disease and it is believed that circulating mi 
RNAs can be used as diagnostic biomarkers for early detec-
tion of disease. Identifying miRNA profiles in the serum/
plasma from certain diseases is ideal, as it is a non-inva-
sive method and miRNAs are highly stable in the blood. It 
was originally thought that the majority of miRNAs within 
the circulation were enclosed within exosomes [134, 135] 
or apoptotic bodies [136], which were released from cells 
into the circulation, allowing cell to cell communication 
and miRNA function in cells distinct from where they were 
synthesized [136]. However, Arroyo et al. [137] used differ-
ential centrifugation and size-exclusion chromatography to 
establish that almost 90 % of circulating miRNAs exist in 
a protein complex (primarily with Ago2, a key molecule in 
miRNA biosynthesis). Biomarkers of disease have already 
been suggested for a number of diseases [138] including 
heart failure, with miR-423-5p distinguishing diseased 
state [139] and type II diabetes mellitus characterized with 
a loss of endothelial miR-126 [140]. There are of course 
difficulties when analyzing miRNA expression from either 
serum or plasma, for instance lack of a standard molecule 
of reference, and further challenges faced in isolating and 
accurately quantifying circulating miRNAs are discussed in 
a review by Zampetaki and Mayr [141]. In addition, ques-
tions still need to be answered on how the circulating miR-
NAs are associated with disease initiation and progression 
and how early these miRNA profiles arise in humans.
Conclusions
MiRNA research is a relatively recent field and there is still 
much to discover about the intricate mechanisms involved 
in the signaling pathways involving miRNAs. It is appar-
ent that miRNAs play a pivotal role in regulating pulmo-
nary arterial remodeling via distinct pathways (Fig. 3). One 
of the biggest challenges in miRNA research is validating 
direct targets of specific miRNAs and hence understanding 
the regulation by which miRNAs exert their effect. Gain- 
and loss-of-function experiments highlight the beneficial 
effects of regulating miRNAs and identification of genes 
involved in the miRNA pathway represent attractive thera-
peutic targets. The most effective therapies will most likely 
target the pathways directly involved in controlling pro-
proliferation and anti-apoptosis of cells within the vessel 
wall and reversing these effects. The modulation of miR-
NAs using either synthetic miRNAs or antimiRs individu-
ally or in combination, is highly studied in animal models 
of PAH, however, there are problems with this treatment. 
The role of miRNAs throughout the body is broad and 
the advantage of therapeutically targeting miRNAs is the 
ability to hit many different pathways involved in disease 
development and progression. However, this can also be a 
significant drawback as targeting a miRNA may produce 
off target effects via modulation of pathways not involved 
in the diseased state. To overcome this problem, highlight-
ing particular targets of selected miRNAs may prove more 
successful in reducing disease severity while limiting the 
effects to pathways involved in PAH. Direct targeting of the 
miRNA via local delivery to the lung is essential to mini-
mize off-target effects. In addition, directing the miRNA 
treatment to particular cellular compartments will further 
reduce unwanted effects. Altogether, the potential to target 
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miRNAs involved in pulmonary remodeling is high and 
will potentially lead to the generation of novel therapeutic 
agents.
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